+

WO2005113598A2 - Membres de la superfamille des tnf avec immunogenicite modifiee - Google Patents

Membres de la superfamille des tnf avec immunogenicite modifiee Download PDF

Info

Publication number
WO2005113598A2
WO2005113598A2 PCT/US2005/018130 US2005018130W WO2005113598A2 WO 2005113598 A2 WO2005113598 A2 WO 2005113598A2 US 2005018130 W US2005018130 W US 2005018130W WO 2005113598 A2 WO2005113598 A2 WO 2005113598A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
agretope
possible modifications
protein
residues
Prior art date
Application number
PCT/US2005/018130
Other languages
English (en)
Other versions
WO2005113598A3 (fr
Inventor
Shannon Alicia Marshall
Gregory L. Moore
Arthur J. Chirino
John R. Desjarlais
Original Assignee
Xencor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor, Inc. filed Critical Xencor, Inc.
Publication of WO2005113598A2 publication Critical patent/WO2005113598A2/fr
Publication of WO2005113598A3 publication Critical patent/WO2005113598A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Definitions

  • the present invention relates to variant Tumor Necrosis Factor Super Family member proteins with reduced immunogenicity. More specifically, the present invention relates to variant BAFF, RANKL, TRAIL, CD40L and APRIL proteins with reduced immunogenicity. In particular, variants of BAFF, RANKL, TRAIL, CD40L and APRIL proteins with reduced ability to bind one or more human class II MHC molecules are described. Background of the Invention
  • Immunogenicity is a major barrier to the development and utilization of protein therapeutics. Although immune responses are typically most severe for non-human proteins, even therapeutics based on human proteins may be immunogenic. Immunogenicity is a complex series of responses to a substance that is perceived as foreign and may include production of neutralizing and non- neutralizing antibodies, formation of immune complexes, complement activation, mast cell activation, inflammation, and anaphylaxis. Several factors can contribute to protein immunogenicity, including but not limited to the protein sequence, the route and frequency of administration, and the patient population.
  • Immunogenicity may limit the efficacy and safety of a protein therapeutic in multiple ways. Efficacy can be reduced directly by the formation of neutralizing antibodies. Efficacy may also be reduced indirectly, as binding to either neutralizing or non-neutralizing antibodies typically leads to rapid clearance from serum. Severe side effects and even death may occur when an immune reaction is raised. One special class of side effects results when neutralizing antibodies cross-react with an endogenous protein and block its function.
  • a more general approach to immunogenicity reduction involves mutagenesis targeted at the agretopes in the protein sequence and structure that are most responsible for stimulating the immune system. Some success has been achieved by randomly replacing solvent-exposed residues to lower binding affinity to panels of known neutralizing antibodies (see for example Laroche et. al. Blood 96: 1425-1432 (2000), entirely incorporated by reference). Due to the enormous diversity of the antibody repertoire, mutations that lower affinity to known antibodies will typically lead to production of an another set of antibodies rather than abrogation of immunogenicity. However, in some cases it may be possible to decrease surface antigenicity by replacing hydrophobic and charged residues on the protein surface with polar neutral residues (see Meyer et. al. Protein Sci. 10: 491-503 (2001), entirely incorporated by reference).
  • BAFF B-cell Activation Factor
  • TNFSF TNF super family
  • BAFF binds three receptors: BAFF-R, TACI, and BCMA.
  • BAFF-R is specific to BAFF while TACI and BCMA are shared with APRIL, another member of TNFSF and the closest homologue of BAFF.
  • Phenotypes of BAFF knockout mice (KO) and a BAFF-R mutant strain of mice (A ⁇ /ySnJ) suggest that BAFF-R is the main receptor for BAFF and is responsible for control of B-cell maturation.
  • TACI controls B-cell homeostasis and T-cell Independent immune response and appears to act as an inhibitory BAFF receptor.
  • BCMA The role of BCMA is unclear thus far.
  • BAFF is an attractive drug target because it has been implicated in the pathogenesis of several diseases and because BAFF inhibitors would potentially have few side effects.
  • a previous invention provided variant BAFF proteins that function as dominant negative or competitive inhibitors of endogenous BAFF.
  • superagonist variants of BAFF were generated, which may serve to stimulate the immune system.
  • BAFF and variant BAFF proteins like all proteins, has the potential to induce unwanted immune responses when used as a therapeutic. Accordingly, the development of therapeutics based on BAFF may be facilitated by preemptively reducing the potential immunogenicity of BAFF or its variants.
  • RANKL is a trimeric TNF family member that binds to the trimeric RANK receptor.
  • RANKL is a key modulator of bone remodeling orchestrated by osteoblasts and osteoclasts. (See US 2003/0013651 and WO 02/080955, entirely incorporated by reference).
  • RANKL activates the receptor RANK upon binding, which leads to the differentiation, survival, and fusion of pre-osteoclasts to form active bone resorbing osteoclasts (see Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T et al. 1998 Cell 93: p. 165-176, entirely incorporated by reference).
  • RANKL also binds to the decoy receptor OPG, which functions as a natural antagonist of RANKL activity.
  • the RANKL biochemical axis has been successfully targeted to treat osteoporosis, rheumatoid arthritis, prosthesis-induced osteolysis, cancer-induced bone destruction, metastasis, hypercalcemia, and pain (Hofbauer et. al. 2001 Cancer 92:460-470; Takahashi et.al. 1999 Biochem. Biophys. Res. Comm. 256:449-455; Honore et al. 2000 Nat. Med. 6:521-528; Oyajobi et.al. 2001 Cancer Res 61 :2572-2578; Childs et. el. J. Bone Mineral Res. 17:192-199, entirely incorporated by reference).
  • RANKL plays a role in the immune system by regulating antigen-specific T cell responses (Anderson et al., Nature 1997, 390:175-179, entirely incorporated by reference).
  • RANKL fragments, analogs, derivatives, or conformers having the ability to bind OPG, which could be used as treatments for a variety of bone diseases have been described (See U.S. Patent No. 5,843,678, entirely incorporated by reference).
  • RANKL variants which induce production of an immune response that down-regulates RANKL activity, have been disclosed (See WO00/15807).
  • utilization of RANKL protein and its derivatives as immune modulators has been proposed (See W099/29865, entirely incorporated by reference).
  • Novel RANKL variants, including variants that express solubly in E. coli, dominant negative variants, competitive inhibitor variants, receptor-specific variants, and superagonist variants have been disclosed (USSN 10/338,785, filed January 6, 2003, entirely incorporated by reference.)
  • a PRoliferation-lnducing Ligand also known as TRDL-1 alpha, TALL-2, and TNFSF-13A, is a member of the TNF Super Family (TNFSF) of proteins.
  • TNFSF TNF Super Family
  • APRIL also participates in a variety of cellular and intracellular signaling processes involved in autoimmune disease, inflammation, and cancer.
  • APRIL is expressed by macrophages, monocytes, dendritic cells, T cells, and a number of human tumors and transformed cell lines. It is synthesized as a type II transmembrane protein, cleaved intracellularly in the Golgi apparatus by a furin convertase, and secreted predominantly as a soluble molecule.
  • a splice variant of the APRIL/TWEAK locus also exists, which results in a functional hybrid molecule (TWE-PRIL) that is primarily retained on the cell surface (Lopez-Fraga et al. EMBO Rep 2: 945-951 (2001), entirely incorporated by reference).
  • APRIL is a sandwich of two anti- parallel beta-sheets with the "jelly roll” or Greek key topology and forms homotrimers typical of the TNFSF.
  • APRIL can also form heterotrimers with BAFF, another member of the TNFSF that is closely related to APRIL.
  • BCMA and TACI B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor (TACI).
  • BCMA preferentially binds APRIL versus BAFF.
  • BCMA and TACI are type III transmembrane proteins, lacking N-terminal signal sequences. The receptors are expressed on B cells and TACI has also been detected on the surface of some T cells.
  • TACI controls B-cell homeostasis and T-cell independent immune response and may act as an inhibitory BAFF receptor. Injection of TACI-lg strongly inhibited or prevented collagen induced arthritis in mice. The role of BCMA is unclear thus far.
  • BCMA and TACI contain intracellular TRAF binding motifs.
  • the signaling mechanisms of these receptors are not fully characterized; however, they appear to mediate activation of the NF-kB, p38, mitogen-activated protein kinase, JNK, AP-1 and NF- AT pathways.
  • APRIL signaling through BCMA and TACI is triggered by binding in its oligomeric (for the most part, trimeric) form.
  • APRIL costimulates B cell proliferation and IgM production and appears to play a role in T- independent type II antigen responses and T cell survival. Accordingly, APRIL may be involved in the pathogenesis of autoimmune and inflammatory conditions.
  • APRIL serum levels inversely correlated with disease in patients with systemic lupus erythematosus (SLE), indicating that APRIL may serve as a down modulator of serological and/or clinical autoimmunity.
  • SLE systemic lupus erythematosus
  • a polymorphism in the APRIL gene has been associated with SLE (67G allele). See for example Tan et al. Arthritis Rheum 48: 982-992 (2003), Roschke et al.
  • APRIL can also induce proliferation/survival of nonlymphoid cells. Elevated expression of APRIL has been found in some tumor cell lines and tumor tissue libraries. Moreover, APRIL-transfected NIH- 3T3 cells show an increased rate of tumor growth in nude mice compared with the parental cell line. APRIL can also protect glioma cells against FasL- and TRAIL-induced apoptosis. These findings suggest that APRIL may be involved in the regulation of tumor cell growth. See Mackay and Ambrose Cytokine Growth Factor Rev 14: 311-324 (2003), Medema et al. Cell Death Differ 10: 1121-1125 (2003), entirely incorporated by reference.
  • APRIL agonists or antagonists may thus be useful in the treatment of oncological, autoimmune, and inflammatory conditions.
  • engineered variants that act as dominant-negative inhibitors, competitive inhibitors, receptor-specific agonists, or superagonists may be used USSN 10/820,465, entirely incorporated by reference.
  • CD40L also known as CD154, TNFSF5, TRAP, and gp39, is a member of the TNF superfamily and may trimerize to bind and activate CD40, as well as alpha Ilb-beta3 integrin.
  • CD40L is a type II membrane glycoprotein of about 33-kDa; the full-length version has 261 amino acids and the extracellular domain (ECD) comprises amino acids 45-261.
  • CD40L is proteolytically processed to yield a soluble form comprising amino acids 113-261. Elevated levels of this soluble form have been established for a variety of disease conditions, including but not limited to: chronic renal failure, diabetes, inflammatory bowel disease, autoimmune thrombocytopenic purpura, Hodgkin's disease, rheumatoid vasculitis, systemic lupus erythrematosis, chronic lymphocytic leukaemia, preeclampsia, sickle cell anemia, atherosclerosis, and numerous cardiovascular conditions. Elevated levels of soluble CD40L have also become well established as a reliable predictor of cardiovascular events.
  • CD40L is transiently expressed after MHC/peptide-induced TCR activation on CD4+T cells. These cells mediate a signal to B cells through the CD40-CD40L interaction, which results in B cell activation. Effects of B cell activation include antibody isotype switching, rescue from apoptosis, germinal center formation, B-cell differentiation and proliferation, and IgE secretion. Mutations in CD40L cause X-linked hyper IgM syndrome, which causes severe immunodeficiency, low levels of IgA, IgG, and IgE, and inability to mount a thymus-dependent humoral response. See Seyama et al. J Biol Chem 274: 1 1310-11320 (1999), Sacco et al. Cancer Gene Ther 7: 1299-1306 (2000), entirely incorporated by reference. The pleiotropic immunologic effects of CD40-CD40L interactions include autoimmunity, transplantation and allograft rejection, as well as control of infection.
  • CD40 and CD40L are also expressed in other cell types including dendritic cells, monocytes, macrophages, endothelial cells, and fibroblasts, and are involved in many inflammatory processes including leukocyte adhesion and migration, induction of chemokines and cytokines, and activation of fibroblasts and platelets.
  • CD40L has been implicated in the pathogenesis of atherosclerosis; it promotes microglial activation and may play a role in the development of Alzheimer's disease.
  • Activation of the CD40-CD40L system also has remarkable antitumor and antimetastatic effects on certain carcinomas. See Laman et al.
  • CD40L has many potential therapeutic indications: anti-tumor or oncological conditions, including Hodgkins and non-Hodgkins lymphomas (NHL), pre- and post-transplantation immunosuppression, psoriasis, rheumatoid and collagen-induced arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), allergic encephalitis, acute and chronic graft versus host disease, Crohn's disease, diabetes, chronic renal failure, mixed connective tissue disease, sickle cell anemia, inflammatory bowel disease, Hodgkin disease, rheumatoid vasculitis, chronic lymphocytic leukaemia, preeclampsia, Alzheimer's disease, and cardiovascular conditions including atherosclerosis, thrombocytopenia (Purpura), etc.
  • HNL Hodgkins and non-Hodgkins lymphomas
  • SLE systemic lupus erythematosus
  • allergic encephalitis acute and
  • Anti-CD40L monoclonal antibodies have shown promise in animal models for the treatment of several chronic inflammatory diseases, autoimmune diseases, and in allograft and transplant rejection. However, clinical experience with CD40L (including monoclonal antibodies) has not yet produced an effective therapeutic. See Dumont Curr Opin Investig Drugs 3: 725-734 (2002), entirely incorporated by reference, discussing monoclonal antibody IDEC-131 ; also the Biogen/Columbia University monoclonal antibody ruplizumab (anti-CD40L) Phase II Antova trial was discontinued due to thrombo-embolic adverse effects.
  • CD40L can activate platelets by signaling through alpha Ilb-beta3 integrin (see for example Prasad et al. Proc Natl Acad Sci U S A 100: 12367-12371 (2003), entirely incorporated by reference.)
  • TNF-related apoptosis inducing ligand also known as Apo2L and TNFSF10
  • Apo2L and TNFSF10 TNF-related apoptosis inducing ligand
  • TNFSF10 TNF-related apoptosis inducing ligand
  • TRAIL forms a homotrimer that binds three receptor molecules, each at the interface between two of its subunits.
  • TRAIL mRNA has been found in a variety of tissues and cells (Wiley et al. Immunity 3: 673-682 (1995)), studies with anti-mTRAIL mAb suggest that only some liver natural killer cells express TRAIL constitutively. However, TRAIL is highly expressed on most natural killer cells after stimulation with IL-2, interferons (IFNs), or IL-15; type I IFN-activated peripheral blood T cells, CD11c+ DC, and monocytes also express TRAIL (see for example Smyth et al. Immunity 18: 1-6 (2003), entirely incorporated by reference).
  • IFNs interferons
  • monocytes also express TRAIL (see for example Smyth et al. Immunity 18: 1-6 (2003), entirely incorporated by reference).
  • Soluble recombinant TRAIL selectively induces apoptosis of a variety of tumor cells and transformed cells, but not most normal cells, and has therefore gained interest as a promising cancer therapeutic, alone or in combination with other cancer treatments. Also, administration to experimental animals including mice and primates produces significant tumor regression without systemic toxicity. TRAIL can induce apoptosis regardless of p53 status, and may be particularly useful in cells where the p53 pathway has been inactivated, thus helping to circumvent resistance to chemo- and radiotherapy. See for example Griffith and Lynch Curr Opin Immunol 10: 559-563 (1998), Ashkenazi et al.
  • TRAIL induces apoptosis through engagement of its death receptors.
  • At least five receptors for TRAIL have been identified in humans.
  • Four are membrane receptors that belong to the TNF receptor family, and two of these, DR4 (TRAIL-R1 ) and DR5 (apo2, TRAIL-R2) are capable of transducing an apoptotic signal.
  • the other receptors, DcR1 (TRAIL-R3), DcR2 (TRAIL-R4), and a soluble receptor called osteoprotegerin (OPG) lack death domains, but may serve as decoy receptors that inhibit TRAIL-mediated cell death when overexpressed.
  • DR5 signals through a FADD- and caspase-8-dependent pathway (Bodmer et al. Nat Cell Biol 2: 241-243 (2000)).
  • the Bcl-2 family member Bax is required for TRAIL-induced apoptosis of certain cancer cell lines, and Bax mutation in mismatch repair-deficient tumors can cause resistance to TRAIL therapy, but preexposure to chemotherapy can rescue tumor sensitivity.
  • mRNA expression of TRAIL death receptors is widely distributed in both normal and malignant tissues (Chaudhary et al. Immunity 7: 821-830 (1997), entirely incorporated by reference), cell surface expression of DR5 has been reported to be elevated in malignant tumor cells.
  • Antibodies that immunospecifically bind to TRAIL receptors, particularly DR4 or DR5 have been shown to induce apoptosis in human tumor cells and are being investigated as potential therapeutics either alone or in combination with other anticancer drugs (see Alderson et al. Proc Amer Assoc Cancer Res 44: Abs 963 (2003), Kaliberov et al.
  • TRAIL Despite pursuit of TRAIL as a selective anticancer therapeutic, little is known about the natural physiological function of TRAIL. TRAIL appears to play an important role in both T-cell and natural killer cell-mediated tumor surveillance and suppression of tumor metastasis, and in anti-viral immune surveillance, often augmented by IFN-regulated induction (Smyth et al. J Exp Med 193: 661-670 (2001 ), Takeda et al. J Exp Med 195: 161-169 (2002), Almasan et al. Cytokine Growth Factor Rev 14: 337-348 (2003), entirely incorporated by reference).
  • TRAIL also has immunosuppressive and immunoregulatory functions that may be protective against autoimmune disorders including diabetes, rheumatoid arthritis, and multiple sclerosis (Song et al. J Exp Med 191 : 1095-1104 (2000), Hilliard et al. J Immunol 166: 1314-1319 (2001), Lamhamedi-Cherradi et al. Diabetes 52: 2274-2278 (2003), Lamhamedi-Cherradi et al. Nat Immunol 4: 255-260 (2003), Patent WO-2004001009 (2003), Patent WO-2004039395 (2004), entirely incorporated by reference. It has been suggested that TRAIL inhibits autoimmune inflammation by blocking cell cycle progression of activated T-cells or by inhibiting cytokine production (Song et al. J Exp Med 191 : 1095-1104 (2000), entirely incorporated by reference).
  • TRAIL has also been reported to play a critical role in inducing hepatic cell death and hepatic inflammation (Zheng et al. J Clin Invest 113: 58-64 (2004), entirely incorporated by reference); thus, TRAIL blockers may be useful in the treatment of hepatitis and other liver diseases.
  • TRA-8 an agonistic monoclonal antibody that binds DR5 but not other TRAIL receptors, is tumoricidal in vitro and in vivo, but unlike TRAIL, does not induce apoptosis of normal hepatocytes; this suggests that specific targeting of DR5 may be a safe and effective strategy for cancer therapy (see lchikawa et al.
  • TNF Super Family members like all proteins, has the potential to induce unwanted immune responses when used as a therapeutic. Accordingly, the development of therapeutics based on TNF Super Family members may be facilitated by preemptively reducing the potential immunogenicity of TNF Super Family members. There remains a need for novel TNF super family member proteins, including but not limited to superagonist, dominant negative, and competitive inhibitor variant TNF super family member proteins, having reduced immunogenicity. Summary of the Invention
  • the present invention provides novel TNF Super Family member proteins having reduced immunogenicity as compared to naturally occurring TNF Super Farnily member proteins.
  • the present invention is directed to methods for engineering or designing less immunogenic proteins with TNF Super Family member activity for therapeutic use.
  • An aspect of the present invention are TNF Super Family member variants that show decreased binding affinity for one or more class II MHC alleles relative to a parent TNF Super Family member and which significantly maintain the activity of native naturally occurring TNF Super Family member.
  • the invention provides recombinant nucleic acids encoding the variant TNF Super Family member proteins, expression vectors, and host cells.
  • the invention provides methods of producing a variant TNF Super Family member protein comprising culturing the host cells of the invention under conditions suitable for expression of the variant TNF Super Family member protein.
  • the invention provides pharmaceutical compositions comprising a variant TNF Super Family member protein or nucleic acid of the invention and a pharmaceutical carrier.
  • the invention provides methods for preventing or treating TNF Super Family member responsive disorders comprising administering a variant TNF Super Family member protein or nucleic acid of the invention to a patient.
  • the invention provides methods for screening the class II MHC haplotypes of potential patients in order to identify individuals who are particularly likely to raise an immune response to a wild type or variant TNF Super Family member therapeutic.
  • the present invention provides TNF Super Family member variant proteins comprising amino acid sequences with at least one amino acid insertion, deletion, or substitution compared to the wild type TNF Super Family member proteins.
  • Figure 1 shows a method for engineering less immunogenic BAFF derivatives.
  • FIG. 1 shows a schematic representation of a method for in vitro testing of the immunogenicity of BAFF peptides or proteins with IVV technology.
  • 9-mer peptide frame and grammatical equivalents herein is meant a linear sequence of nine amino acids that is located in a protein of interest. 9-mer frames may be analyzed for their propensity to bind one or more class II MHC alleles.
  • allele and grammatical equivalents herein is meant an alternative form of a gene. Specifically, in the context of class II MHC molecules, alleles comprise all naturally occurring sequence variants of DRA, DRB1 , DRB3/4/5, DQA1 , DQB1 , DPA1 , and DPB1 molecules.
  • TNF Super Family member responsive disorders or conditions diseases, disorders, and conditions that can benefit from treatment with TNF Super Family member proteins.
  • TNF Super Family member-responsive disorders include, but are not limited to, autoimmune diseases such as systemic lupus erythematosus, diabetes, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, Crohn's Disease, and psoriasis; transplant rejection and graft versus host disease; hematological cancers such as Hodgkin's lymphoma, non-Hodgkin's lymphomas (Burkitt's lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, mycosis fungoides, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, hairy cell leukemia and lymphoplasmacvtic le
  • autoimmune diseases such as systemic lupus
  • a hit and grammatical equivalents herein is meant, in the context of the matrix method, that a given peptide is predicted to bind to a given class II MHC allele.
  • a hit is defined to be a peptide with binding affinity among the top 5%, or 3%, or 1 % of binding scores of random peptide sequences.
  • a hit is defined to be a peptide with a binding affinity that exceeds some threshold, for instance a peptide that is predicted to bind an MHC allele with at least 100 ⁇ M or 10 ⁇ M or 1 ⁇ M affinity.
  • immunogenicity and grammatical equivalents herein is meant the ability of a protein to elicit an immune response, including but not limited to production of neutralizing and non-neutralizing antibodies, formation of immune complexes, complement activation, mast cell activation, inflammation, and anaphylaxis.
  • reduced immunogenicity and grammatical equivalents herein is meant a decreased ability to activate the immune system, when compared to the wild type protein.
  • a variant protein can be said to have “reduced immunogenicity” if it elicits neutralizing or non-neutralizing antibodies in lower titer or in fewer patients than the wild type protein.
  • the probability of raising neutralizing antibodies is decreased by at least 5%, with at least 50% or 90% decreases being especially preferred. So, if a wild type produces an immune response in 10% of patients, a variant with reduced immunogenicity would produce an immune response in not more than 9.5% of patients, with less than 5% or less than 1% being especially preferred.
  • a variant protein also can be said to have "reduced immunogenicity" if it shows decreased binding to one or more MHC alleles or if it induces T-cell activation in a decreased fraction of patients relative to the parent protein.
  • the probability of T-cell activation is decreased by at least 5%, with at least 50% or 90% decreases being especially preferred.
  • matrix method and grammatical equivalents thereof herein is meant a method for calculating peptide - MHC affinity in which a matrix is used that contains a score for each possible residue at each position in the peptide, interacting with a given MHC allele.
  • the binding score for a given peptide - MHC interaction is obtained by summing the matrix values for the amino acids observed at each position in the peptide.
  • MHC-binding agretopes and grammatical equivalents herein is meant peptides that are capable of binding to one or more class II MHC alleles with appropriate affinity to enable the formation of MHC - peptide - T-cell receptor complexes and subsequent T-cell activation.
  • MHC- binding agretopes are linear peptide sequences that comprise at least approximately 9 residues.
  • parent protein as used herein is meant a protein that is subsequently modified to generate a variant protein. Said parent protein may be a wild-type or naturally occurring protein, or a variant or engineered version of a naturally occurring protein.
  • Parent protein may refer to the protein itself, compositions that comprise the parent protein, or any amino acid sequence that encodes it. Accordingly, by “parent TNF Super Family member protein” as used herein is meant a TNF Super Family member protein that is modified to generate a variant TNF Super Family member protein.
  • patient herein is meant both humans and other animals, particularly mammals, and organisms. Thus the methods are applicable to both human therapy and veterinary applications.
  • the patient is a mammal, and in the most preferred embodiment the patient is human.
  • protein herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides.
  • the protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures, i.e., "analogs” such as peptoids [see Simon et al., Proc. Natl. Acad. Sci. U.S.A. 89(20:9367-71 (1992), entirely incorporated by reference], generally depending on the method of synthesis.
  • amino acids for the purposes of the invention.
  • amino acid also includes amino acid residues such as proline and hydroxyproline. Both D- and L- amino acids may be utilized.
  • treatment herein is meant to include therapeutic treatment, as well as prophylactic, or suppressive measures for the disease or disorder.
  • successful administration of a variant TNF Super Family member protein prior to onset of the disease may result in treatment of the disease.
  • successful administration of a variant TNF Super Family member protein after clinical manifestation of the disease to combat the symptoms of the disease comprises “treatment" of the disease.
  • Treatment also encompasses administration of a variant TNF Super Family member protein after the appearance of the disease in order to eradicate the disease. Successful administration of an agent after onset and after clinical symptoms have developed, with possible abatement of clinical symptoms and perhaps amelioration of the disease, further comprises “treatment” of the disease. Those "in need of treatment” include mammals already having the disease or disorder, as well as those prone to having the disease or disorder, including those in which the disease or disorder is to be prevented.
  • variant TNF Super Family member nucleic acids and grammatical equivalents herein is meant nucleic acids that encode variant TNF Super Family member proteins.
  • variant TNF Super Family member proteins are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the TNF Super Family member protein sequence.
  • the TNF Super Family member variants typically either exhibit biological activity that is comparable to naturally occurring TNF Super Family member or have been specifically engineered to have alternate biological properties.
  • the variant TNF Super Family member proteins may contain insertions, deletions, and/or substitutions at the N-terminus, C-terminus, or internally.
  • variant TNF Super Family member proteins have at least 1 residue that differs from the naturally occurring TNF Super Family member sequence, with at least 2, 3, 4, or 5 different residues being more preferred.
  • Variant TNF Super Family member proteins may contain further modifications, for instance mutations that alter stability or solubility or which enable or prevent posttranslational modifications such as PEGylation or glycosylation.
  • Variant TNF Super Family member proteins may be subjected to co- or post-translational modifications, including but not limited to synthetic derivatization of one or more side chains or termini, glycosylation, PEGylation, circular permutation, cyclization, fusion to proteins or protein domains, and addition of peptide tags or labels.
  • wild type or wt and grammatical equivalents thereof herein is meant an amino acid sequence or a nucleotide sequence that is found in nature and includes allelic variations; that is, an amino acid sequence or a nucleotide sequence that has not been intentionally modified.
  • the wild type sequence is SEQJD NO:1.
  • MHC-binding peptides are obtained from proteins by a process called antigen processing.
  • the protein is transported into an antigen presenting cell (APC) by endocytosis or phagocytosis.
  • a variety of proteolytic enzymes then cleave the protein into a number of peptides.
  • These peptides can then be loaded onto class II MHC molecules, and the resulting peptide-MHC complexes are transported to the cell surface.
  • Relatively stable peptide-MHC complexes can be recognized by T-cell receptors that are present on the surface of naive T cells. This recognition event is required for the initiation of an immune response. Accordingly, blocking the formation of stable peptide-MHC complexes is an effective approach for preventing unwanted immune responses.
  • MHC-binding propensity scores are calculated for each 9-residue frame along the TNF Super Family sequence using a matrix method (see Sturniolo et. al., supra; Marshall et al., J. Immunol. 154: 5927-5933 (1995), and Hammer et. al., J. Exp. Med. 180: 2353-2358 (1994), entirely incorporated by reference). It is also possible to consider scores for only a subset of these residues, or to consider also the identities of the peptide residues before and after the 9-residue frame of interest.
  • the matrix comprises binding scores for specific amino acids interacting with the peptide binding pockets in different human class II MHC molecule.
  • the scores in the matrix are obtained from experimental peptide binding studies.
  • scores for a given amino acid binding to a given pocket are extrapolated from experimentally characterized alleles to additional alleles with identical or similar residues lining that pocket. Matrices that are produced by extrapolation are referred to as "virtual matrices”.
  • the matrix method is used to calculate scores for each peptide of interest binding to each allele of interest. Several methods can then be used to determine whether a given peptide will bind with significant affinity to a given MHC allele.
  • the binding score for the peptide of interest is compared with the binding propensity scores of a large set of reference peptides. Peptides whose binding propensity scores are large compared to the reference peptides are likely to bind MHC and may be classified as "hits". For example, if the binding propensity score is among the highest 1 % of possible binding scores for that allele, it may be scored as a "hit" at the 1% threshold.
  • the total number of hits at one or more threshold values is calculated for each peptide.
  • the binding score may directly correspond with a predicted binding affinity.
  • a hit may be defined as a peptide predicted to bind with at least 100 ⁇ M or 10 ⁇ M or 1 ⁇ M affinity.
  • the number of hits for each 9-mer frame in the protein is calculated using one or more threshold values ranging from 0.5% to 10%. In an especially preferred embodiment, the number of hits is calculated using 1%, 3%, and 5% thresholds.
  • MHC-binding agretopes are identified as the 9-mer frames that bind to several class II MHC alleles. In an especially preferred embodiment, MHC-binding agretopes are predicted to bind at least 10 alleles at 5% threshold and/or at least 5 alleles at 1% threshold. Such 9-mer frames may be especially likely to elicit an immune response in many members of the human population.
  • MHC-binding agretopes are predicted to bind MHC alleles that are present in at least 0.01 - 10 % of the human population.
  • MHC-binding agretopes are predicted to bind MHC alleles that are present in at least 0.01 - 10 % of the relevant patient population.
  • MHC binding agretopes are predicted for MHC heterodimers comprising highly prevalent MHC alleles.
  • Class II MHC alleles that are present in at least 10 % of the US population include but are not limited to: DPA1*0103, DPA1*0201 , DPB1*0201 , DPB1*0401, DPB1*0402, DQA1*0101, DQA1*0102, DQA1*0201, DQA1 *0501, DQB1 *0201, DQB1 *0202, DQB1*0301 , DQB1*0302, DQB1*0501 , DQB1 *0602, DRA * 0101 , DRB1 * 0701 , DRB1*1501 , DRB1*0301, DRB1*0101, DRB1*1101, DRB1*1301, DRB3*0101, DRB3*0202, DRB4*0101, DRB4*0103
  • MHC binding agretopes are also predicted for MHC heterodimers comprising moderately prevalent MHC alleles.
  • Class II MHC alleles that are present in 1% to 10% of the US population include but are not limited to: DPA1*0104, DPA1*0302, DPA1*0301 , DPB1*0101 DPB1 * 0202, DPB1*0301 , DPB1* 0501 , DPB1*0601 , DPB1*0901 , DPB1*1001 , DPB1*1101 DPB1*1301 , DPB1*1401, DPB1*1501 , DPB1*1701, DPB1*1901 , DPB1*2001, DQA1 * 0103 DQA1*0104, DQA1*0301 , DQA1*0302, DQA1*0401 , DQB1*0303, DQB1*0402, DQB1*0502 DQB1*05
  • MHC binding agretopes may also be predicted for MHC heterodimers comprising less prevalent alleles.
  • Information about MHC alleles in humans and other species can be obtained, for example, from the IMGT/HLA sequence database (.ebi.ac.uk/imgt/hla/).
  • an immunogenicity score is determined for each peptide, wherein said score depends on the fraction of the population with one or more MHC alleles that are hit at multiple thresholds.
  • Iscore N( W.,P ⁇ + W 3 P + W 5 P 5 ) may be used, where P- is the percent of the population hit at 1%, P 3 is the percent of the population hit at 3%, P 5 is the percent of the population hit at 5%, each W is a weighting factor, and N is a normalization factor.
  • agretopes with Iscore greater than or equal to 10 are preferred and agretopes with Iscore greater than or equal to 25 are especially preferred.
  • Preferred MHC-binding agretopes are those agretopes that are predicted to bind at a 3% threshold to MHC alleles and are present in at least 5% of the population.
  • MHC-binding agretopes are identified as the 9-mer frames that are located among "nested" agretopes, or overlapping 9-residue frames that are each predicted to bind a significant number of alleles. Such sequences may be especially likely to elicit an immune response.
  • Preferred MHC-binding agretopes are those agretopes that are predicted to bind, at a 3% threshold, to MHC alleles that are present in at least 5% of the population.
  • Especially preferred MHC- binding agretopes are those agretopes that are predicted to bind, at a 1% threshold, to MHC alleles that are present in at least 10% of the population.
  • Preferred MHC-binding agretopes in BAFF include, but are not limited to, agretope 2: residues 168-176; agretope 3: residues 169-177; agretope 6: residues 192-200; agretope 7: residues 193-201 ; agretope 9: residues 200-208; agretope 10: residues 212-220; agretope 12: residues 226-234; agretope 14: residues 230-238; agretope 16: residues 276-284.
  • Especially preferred MHC-binding agretopes in BAFF include, but are not limited to, agretope 2: residues 168-176; agretope 6: residues 192-200; agretope 9: residues 200-208; agretope 10: residues 212-220; agretope 12: residues 226- 234; agretope 16: residues 276-284.
  • Preferred MHC-binding agretopes in RANKL include, but are not limited to, agretope 2: residues 207-215; agretope 3: residues 213-221 ; agretope 4: residues 214-222; agretope 5: residues 215-223 agretope 6: residues 222-230; agretope 9: residues 238-246; agretope 10: residues 239-247 agretope 12: residues 241-249; agretope 14: residues 270-278; agretope 15: residues 277-285; agretope 17: residues 289-297; agretope 18: residues 308-316.
  • Especially preferred MHC-binding agretopes in RANKL include, but are not limited to, agretope 3: residues 213-221 ; agretope 4: residues 214-222; agretope 10: residues 239-247; agretope 12: residues 241-249; agretope 15: residues 277-285; agretope 17: residues 289-297.
  • Preferred MHC-binding agretopes in APRIL include, but are not limited to, agretope 1 : residues 117-125; agretope 2: residues 120-128; agretope 4: residues 138-146; agretope 5: residues 142-150; agretope 6: residues 155-163; agretope 7: residues 162-170; agretope 9: residues 164-172; agretope 10: residues 170-178; agretope 11: residues 194-202; agretope 12: residues 197-205; agretope 15: residues 228-236.
  • Especially preferred MHC-binding agretopes in APRIL include, but are not limited to, agretope 5: residues 142-150; agretope 9: residues 164-172; agretope 10: residues 170-178; agretope 11 : residues 194-202.
  • Preferred MHC-binding agretopes in CD40L include, but are not limited to, agretope 1 : residues 145-153; agretope 2: residues 146-154; agretope 3: residues 152-160; agretope 4: residues 168-176; agretope 5: residues 169-177; agretope 6: residues 170-178; agretope 7: residues 171-179; agretope 9: residues 189-197; agretope 10: residues 204-212; agretope 11 : residues 205-213; agretope 12: residues 206-214; agretope 13: residues 223-231 ; agretope 14: residues 229-237; agretope 15: residues 237-245.
  • MHC-binding agretopes in CD40L include, but are not limited to, agretope 12: residues 206-214.
  • Preferred MHC-binding agretopes in TRAIL include, but are not limited to, agretope 1 : residues 151-159; agretope 2: residues 174-182; agretope 3: residues 181-189; agretope 6: residues 206-214; agretope 7: residues 207-215; agretope 9: residues 220-228; agretope 10: residues 221-229; agretope 12: residues 237-245; agretope 14: residues 256-264; agretope 15: residues 257-265.
  • Especially preferred MHC-binding agretopes in TRAIL include, but are not limited to, agretope 2: residues 174-182; agretope 7: residues 207-215; agretope 10: residues 221-229; agretope 14: residues 256-264; agretope 15: residues 257-265.
  • the immunogenicity of the above-predicted MHC-binding agretopes is experimentally confirmed by measuring the extent to which peptides comprising each predicted agretope can elicit an immune response.
  • T cells and antigen presenting cells from matched donors can be stimulated with a peptide containing an agretope of interest, and T-cell activation can be monitored. It is also possible to first stimulate T cells with the whole protein of interest, and then re- stimulate with peptides derived from the whole protein. If sera are available from patients who have raised an immune response to TNF Super Family, it is possible to detect mature T cells that respond to specific epitopes.
  • interferon gamma or IL-5 production by activated T- cells is monitored using Elispot assays, although it is also possible to use other indicators of T-cell activation or proliferation such as tritiated thymidine incorporation or production of other cytokines.
  • HLA genotype is a major determinant of susceptibility to specific autoimmune diseases (see for example Nepom Clin. Immunol. Immunopathol. 67: S50-S55 (1993), entirely incorporated by reference) and infections (see for example Singh et. al. Emerg. Infect. Dis. 3: 41-49 (1997), entirely incorporated by reference). Furthermore, the set of MHC alleles present in an individual can affect the efficacy of some vaccines (see for example Cailat-Zucman et. al. Kidney Int. 53: 1626-1630 (1998) and Tru et. al. Vaccine 20: 430-438 (2001), both entirely incorporated by reference). HLA genotype may also confer susceptibility for an individual to elicit an unwanted immune response to a TNF Super Family therapeutic.
  • class II MHC alleles that are associated with increased or decreased susceptibility to elicit an immune response to TNF Super Family proteins are identified.
  • patients treated with TNF Super Family therapeutics may be tested for the presence of anti-TNF Super Family antibodies and genotyped for class II MHC.
  • T-cell activation assays such as those described above may be conducted using cells derived from a number of genotyped donors. Alleles that confer susceptibility to TNF Super Family immunogenicity may be defined as those alleles that are significantly more common in those who elicit an immune response versus those who do not.
  • alleles that confer resistance to TNF Super Family immunogenicity may be defined as those that are significantly less common in those who do not elicit an immune response versus those that do. It is also possible to use purely computational techniques to identify which alleles are likely to recognize TNF Super Family therapeutics. In one embodiment, the genotype association data is used to identify patients who are especially likely or especially unlikely to raise an immune response to a TNF Super Family therapeutic.
  • the above-determined MHC-binding agretopes are replaced with alternate amino acid sequences to generate active variant TNF Super Family proteins with reduced or eliminated immunogenicity.
  • the MHC-binding agretopes are modified to introduce one or more sites that are susceptible to cleavage during protein processing. If the agretope is cleaved before it binds to a MHC molecule, it will be unable to promote an immune response.
  • one or more possible alternate 9-mer sequences are analyzed for immunogenicity as well as structural and functional compatibility.
  • the preferred alternate 9-mer sequences are then defined as those sequences that have low predicted immunogenicity and a high probability of being structured and active. It is possible to consider only the subset of 9-mer sequences that are most likely to comprise structured, active, less immunogenic variants. For example, it may be unnecessary to consider sequences that comprise highly non-conservative mutations or mutations that increase predicted immunogenicity.
  • less immunogenic variants of each agretope are predicted to bind MHC alleles in a smaller fraction of the population than the wild type agretope.
  • the less immunogenic variant of each agretope is predicted to bind to MHC alleles that are present in not more than 5 % of the population, with not more than 1 % or 0.1 % being most preferred.
  • substitution matrices or other knowledge-based scoring methods are used to identify alternate sequences that are likely to retain the structure and function of the wild type protein. Such scoring methods can be used to quantify how conservative a given substitution or set of substitutions is. In most cases, conservative mutations do not significantly disrupt the structure and function of proteins (see for example, Bowie et. al. Science 247: 1306-1310 (1990), Bowie and Sauer Proc. Nat. Acad. Sci. USA 86: 2152-2156 (1989), and Reidhaar-Olson and Sauer Proteins 7: 306-316 (1990), entirely incorporated by reference). However, non-conservative mutations can destabilize protein structure and reduce activity (see for example, Lim et. al. Biochem.
  • Substitution matrices including but not limited to BLOSUM62 provide a quantitative measure of the compatibility between a sequence and a target structure, which can be used to predict non-disruptive substitution mutations (see Topham et al. Prot. Eng. 10: 7-21 (1997), entirely incorporated by reference). The use of substitution matrices to design peptides with improved properties has been disclosed; see Adenot et al. J. Mol. Graph. Model. 17: 292-309 (1999), entirely incorporated by reference. [73] Substitution matrices include, but are not limited to, the BLOSUM matrices (Henikoff and Henikoff, Proc. Nat. Acad. Sci.
  • substitution matrices see for example Henikoff Curr. Opin. Struct. Biol. 6: 353-360 (1996), entirely incorporated by reference. It is also possible to construct a substitution matrix based on an alignment of a given protein of interest and its homologs; see for example Henikoff and Henikoff Comput. Appl. Biosci. 12: 135-143 (1996), entirely incorporated by reference.
  • each of the substitution mutations that are considered has a BLOSUM 62 score of zero or higher. According to this metric, preferred substitutions include, but are not limited to:
  • the total BLOSUM 62 score of an alternate sequence for a nine residue MHC-binding agretope is decreased only modestly when compared to the BLOSUM 62 score of the wild type nine residue agretope.
  • the score of the variant 9-mer is at least 50 % of the wild type score, with at least 67%, 75%, 80% or 90% being more preferred.
  • alternate sequences can be selected that minimize the absolute reduction in BLOSUM score; for example it is preferred that the score decrease for each 9-mer is less than 20, with score decreases of less than about 10 or about 5 being especially preferred.
  • the exact value may be chosen to produce a library of alternate sequences that is experimentally tractable and also sufficiently diverse to encompass a number of active, stable, less immunogenic variants.
  • substitution mutations are preferentially introduced at positions that are substantially solvent exposed.
  • solvent exposed positions are typically more tolerant of mutation than positions that are located in the core of the protein.
  • substitution mutations are preferentially introduced at positions that are not highly conserved.
  • positions that are highly conserved among members of a protein family are often important for protein function, stability, or structure, while positions that are not highly conserved often may be modified without significantly impacting the structural or functional properties of the protein.
  • one or more alanine substitutions may be made, regardless of whether an alanine substitution is conservative or non-conservative. As is known in the art, incorporation of sufficient alanine substitutions may be used to disrupt intermolecular interactions.
  • variant 9-mers are selected such that residues that have been or can be identified as especially critical for maintaining the structure or function of TNF Super Family retain their wild type identity. In alternate embodiments, it may be desirable to produce variant TNF Super Family proteins that do not retain wild type activity. In such cases, residues that have been identified as critical for function may be specifically targeted for modification.
  • Positions that mediate binding to the receptors BAFF-R, TACI, and BCMA include, but are not limited to, Q159, Y163, D203, T205, Y206, A207, L211 , R231 , I233, P264, R265, and D275, more preferably D203, T205, Y206, I233, R265, and D275.
  • Residues that may impact the oligomer subunit exchange properties of BAFF include, but are not limited to, T205, Y206, F220, E223, V227, T228, I233, L240, D273 and D275.
  • RANKL contacts its receptor, RANK, and its decoy receptor, OPG, through three dimensional epitopes located in the Large Domain, the Small Domain, and the DE loop. Modifications to the receptor contact positions are expected to have direct effects on receptor binding or signaling. Positions that contact receptor include, but are not limited to, the Large Domain positions 172, 187- 193, 222-228, 267-270, 297, and 300-302; the Small Domain positions 179-183 and 233-241 ; and the DE Loop positions 246-253 and 284.
  • RANKL is active as a trimer. Accordingly, modifications to the trimer interface positions are expected to have direct effects on RANKL activity.
  • the trimer Interface includes positions 163, 165, 167, 193, 195, 213, 215, 217, 219, 221 , 235, 237, 239, 244, 253-264, 268, 271-282, 300, 302, 304- 305, 307, 311 , and 313-314.
  • residues may be targeted for mutagenesis in order to yield a APRIL variant that functions as an antagonist, receptor specific agonist, or superagonist.
  • Suitable residues include but are not limited to Large Domain receptor contact residues (positions 121, 139-142, 170- 174, 205-208, and 237-241 ), Small Domain receptor contact residues (positions 175-181 and 195- 197), and DE loop receptor contact residues (positions 186-190).
  • trimer interface positions may be modified, for example to promote trimer exchange or to stabilize desired trimeric structures.
  • Trimer interface positions include but are not limited to residues 115, 117, 119, 142, 144, 162, 164, 166, 168, 170, 176, 177, 192, 194, 201 , 208-216, 237, 239, 241 , 242, 245, 248, 250, and 251.
  • Especially preferred trimer interface positions are APRIL positions 142, 144, 162, 164, 216 and 251.
  • CD40L mutations associated with the X-linked form of hyper-lgM syndrome disrupt the normal function of CD40L; these mutations include A123E, H125R, V126D, V126A, W140C, W140G, W140R, W140X, G144E, T147N, L155P, Y170P, A173D, Q174R, T176I, A183@, S184X, Q186X, L193@, L195P, R200X, E202X, A208D, C218X, Q220X, Q221X, H224Y, G226A, G227V, L231S, Q232X, A235P, S236X, V237E, T254M, G257D, G257S, and L258S, where X denotes a deletion of the amino acid and @ denotes insertions of one or more amino acids at these locations (uta.fi/imt/bioinfo/CD40Lbase).
  • residues may be targeted for mutagenesis in order to yield a CD40L variant that functions as an antagonist of wild type CD40L protein or as a superagonist of CD40.
  • Suitable residues include but are not limited to Large Domain receptor contact residues (positions 28- 34, 63-69, 112-115, and 137-14), Small Domain receptor contact residues (positions 72-79 and 95- 98), and DE loop receptor contact residues (positions 84-89).
  • trimer interface positions may be modified, for example to promote trimer exchange or to stabilize desired trimeric structures.
  • Trimer interface positions include but are not limited to residues 11 , 13, 15, 34, 36, 53-55, 57, 59, 61 , 63, 72, 73, 75, 77, 119, 87, 91-99, 102-104, 109, 112-125, 147-149, 151 , and 155-157.
  • Especially preferred trimer interface positions to be modified are positions 57, 34, and 91.
  • a zinc atom coordinated by three symmetry-related Cys230 residues in the trimerization interface appears essential for trimer stability and optimal biological activity; mutation of Cys230 to alanine or serine results in 20- and 70-fold reductions in apoptotic activity, respectively, decreases receptor binding by at least 200-fold, and reduces the stability of the trimeric structure.
  • Removal of zinc from wild type TRAIL by dialysis with chelating agents results in a significant decrease in receptor binding affinity and a 90-fold reduction in apoptotic activity; zinc depleted TRAIL forms poorly active, disulfide- linked dimers. See Bodmer et al. J Biol Chem 275: 20632-20637 (2000), Hymowitz et al. Biochemistry 39: 633-640 (2000), entirely incorporated by reference.
  • deletion of the AA" insertion loop (TRAIL residues 137-152) and point mutants of residues believed to interact with the receptor (E144N/K on the ⁇ turn of the AA" loop, D218N/K on the DE loop and D267N/K on the GH loop) resulted in decreased or no cytotoxic activity using a Jurkat T cell assay.
  • Decreased cytotoxic activity or sDR5 binding was also obtained with other TRAIL variants containing deletions in the AA" loop (residues 132-135, Ser-Leu- Leu sequence instead of residues 135-153).
  • LZ-TRAIL Leucine zippers introduced to the N-terminus to facilitate multimerization result in mutants (LZ- TRAIL) that are superior to normal and cross-linked TRAIL in causing cell lysis in human and mouse cell lines; LZ-TRAIL also confers survival to tumor challenge in mice without hepatotoxicity.
  • Protein design methods and MHC agretope identification methods may be used together to identify stable, active, and minimally immunogenic protein sequences (see WO03/006154, entirely incorporated by reference).
  • the combination of approaches provides significant advantages over the prior art for immunogenicity reduction, as most of the reduced immunogenicity sequences identified using other techniques fail to retain sufficient activity and stability to serve as therapeutics.
  • Protein design methods may identify non-conservative or unexpected mutations that nonetheless confer desired functional properties and reduced immunogenicity, as well as identifying conservative mutations.
  • Nonconservative mutations are defined herein to be all substitutions not included in Table 1 above; nonconservative mutations also include mutations that are unexpected in a given structural context, such as mutations to hydrophobic residues at the protein surface and mutations to polar residues in the protein core.
  • protein design methods may identify compensatory mutations. For example, if a given first mutation that is introduced to reduce immunogenicity also decreases stability or activity, protein design methods may be used to find one or more additional mutations that serve to recover stability and activity while retaining reduced immunogenicity. Similarly, protein design methods may identify sets of two or more mutations that together confer reduced immunogenicity and retained activity and stability, even in cases where one or more of the mutations, in isolation, fails to confer desired properties.
  • a wide variety of methods are known for generating and evaluating sequences. These include, but are not limited to, sequence profiling (Bowie and Eisenberg, Science 253(5016): 164-70, (1991)), residue pair potentials (Jones, Protein Science 3: 567-574, (1994)), and rotamer library selections (Dahiyat and Mayo, Protein Sci 5(5): 895-903 (1996); Dahiyat and Mayo, Science 278(5335): 82-7 (1997); Desjarlais and Handel, Protein Science 4: 2006-2018 (1995); Harbury et al, PNAS USA 92(18): 8408-8412 (1995); Kono et al., Proteins: Structure, Function and Genetics 19: 244-255 (1994); Hellinga and Richards, PNAS USA 91 : 5803-5807 (1994), entirely incorporated by reference).
  • PDA® technology couples computational design algorithms that generate quality sequence diversity with experimental high-throughput screening to discover proteins with improved properties.
  • PDA® utilizes three-dimensional structural information.
  • the computational component uses atomic level scoring functions, side chain rotamer sampling, and advanced optimization methods to accurately capture the relationships between protein sequence, structure, and function. Calculations begin with the three-dimensional structure of the protein and a strategy to optimize one or more properties of the protein.
  • PDA® technology explores the sequence space comprising all pertinent amino acids (including unnatural amino acids, if desired) at the positions targeted for design.
  • the structure of a TNF Super Family member is determined using X-ray crystallography or NMR methods, which are well known in the art. Crystal structures of some human TNF Super Family members have been solved to high resolution: human BAFF (PDB code 1 KXG; Oren et al. 2002 Nat. Struct. Biol. 9: 288), human TRAIL (PDB code 1D4V; Mongkolsapaya et al. 1999 Nat. Struct. Biol. 6:1043), human CD40L (PDB code 1ALY; Karpusas et al. 1995 Structure 3:1426), all entirely incorporated by reference.
  • the structures of human RANKL and APRIL were determined using the sequences of human RANKL and human APRIL and the structures of murine RANKL (PDB code 1 IQA; lto et al. 2002 J. Biol. Chem. 277: 6631) and murine APRIL (PDB code 1XU2; Hymowitz et al. 2005 J. Biol. Chem. 280:7218), both entirely incorporated by reference.
  • crystal structures of the BAFF / BAFF-R complex (PDB codes 10TZ and 1 P0T; Kim et. al. 2003 Nat. Struct. Biol.
  • the results of matrix method calculations are used to identify which of the 9 amino acid positions within the agretope(s) contribute most to the overall binding propensities for each particular allele "hit". This analysis considers which positions (P1-P9) are occupied by amino acids which consistently make a significant contribution to MHC binding affinity for the alleles scoring above the threshold values. Matrix method calculations are then used to identify amino acid substitutions at said positions that would decrease or eliminate predicted immunogenicity and PDA® technology is used to determine which of the alternate sequences with reduced or eliminated immunogenicity are compatible with maintaining the structure and function of the protein.
  • the residues in each agretope are first analyzed by one skilled in the art to identify alternate residues that are potentially compatible with maintaining the structure and function of the protein. Then, the set of resulting sequences are computationally screened to identify the least immunogenic variants. Finally, each of the less immunogenic sequences are analyzed more thoroughly in PDA® technology protein design calculations to identify protein sequences that maintain the protein structure and function and decrease immunogenicity.
  • each residue that contributes significantly to the MHC binding affinity of an agretope is analyzed to identify a subset of amino acid substitutions that are potentially compatible with maintaining the structure and function of the protein.
  • This step may be performed in several ways, including PDA® calculations or visual inspection by one skilled in the art. Sequences may be generated that contain all possible combinations of amino acids that were selected for consideration at each position. Matrix method calculations can be used to determine the immunogenicity of each sequence. The results can be analyzed to identify sequences that have significantly decreased immunogenicity. Additional PDA® calculations may be performed to determine which of the minimally immunogenic sequences are compatible with maintaining the structure and function of the protein.
  • pseudo-energy terms derived from the peptide binding propensity matrices are incorporated directly into the PDA® technology calculations. In this way, it is possible to select sequences that are active and less immunogenic in a single computational step.
  • more than one method is used to generate variant proteins with desired functional and immunological properties.
  • substitution matrices may be used in combination with PDA® technology calculations.
  • Strategies for immunogenicity reduction include, but are not limited to, those described in USSN 11/004,590, filed December 3, 2004, entirely incorporated by reference.
  • a variant protein with reduced binding affinity for one or more class II MHC alleles is further engineered to confer improved solubility.
  • protein aggregation may contribute to unwanted immune responses, increasing protein solubility may reduce immunogenicity (see for example SIFN).
  • a variant protein with reduced binding affinity for one or more class II MHC alleles is further modified by derivitization with PEG or another molecule.
  • PEG may sterically interfere with antibody binding or improve protein solubility, thereby reducing immunogenicity.
  • rational PEGylation methods are used USSN 10/956,352, filed September 30, 2004, entirely incorporated by reference.
  • PDA® technology and matrix method calculations are used to remove more than one MHC-binding agretope from a protein of interest.
  • Variant TNF Super Family proteins of the invention and nucleic acids encoding them may be produced using a number of methods known in the art.
  • nucleic acids encoding the TNF Super Family variants are prepared by total gene synthesis, or by site-directed mutagenesis of a nucleic acid encoding a parent TNF Super Family protein. Methods including template-directed ligation, recursive PCR, cassette mutagenesis, site-directed mutagenesis or other techniques that are well known in the art may be utilized (see for example Strizhov et al. PNAS 93:15012-15017 (1996), Prodromou and Perl, Prot. Eng. 5: 827-829 (1992), Jayaraman and Puccini, Biotechniques 12: 392-398 (1992), and Chalmers et al. Biotechniques 30: 249-252 (2001)), entirely incorporated by reference.
  • TNF Super Family variants are cloned into an appropriate expression vector and expressed in E. coli (see McDonald, J.R., Ko, C, Mismer, D., Smith, D.J. and Coliins, F. Biochim. Biophys. Acta 1090: 70-80 (1991 ), entirely incorporated by reference).
  • TNF Super Family variants are expressed in mammalian cells, yeast, baculovirus, or in vitro expression systems.
  • the TNF Super Family variants are purified or isolated after expression.
  • Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing.
  • a TNF Super Family variant may be purified using a standard anti-recombinant protein antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful.
  • suitable purification techniques see Scopes, R., Protein Purification, Springer-Verlag, NY, 3rd ed. (1994), entirely incorporated by reference. The degree of purification necessary will vary depending on the desired use, and in some instances no purification will be necessary.
  • the variant TNF Super Family proteins of the invention may be tested for activity using any of a number of methods, including but not limited to those described below. Suitable binding assays may be used.
  • the kinetic association rate (K on ) and dissociation rate (K 0ff ), and the equilibrium binding constants (K d ) may be determined using surface plasmon resonance on a BIAcore instrument following the standard procedure in the literature [Pearce et al., Biochemistry 38:81-89 (1999), entirely incorporated by reference].
  • Binding affinity and kinetics may also be characterized using proximity assays such as AlphaScreenTM (Packard BioScience®) or microcalorimetry (Isothermal Titration Calorimetry, Differential Scanning Calorimetry), entirely incorporated by reference.
  • Cell-based activity assays include but are not limited to, NF-kB nuclear translocation (Wei et al., Endocrinology 142, 1290-1295, (2001 )) or c-Jun (Srivastava et al., JBC 276, 8836-8840 (2001), entirely incorporated by reference) transcription factor activation assays, B-cell proliferation assays, and IgE secretion assays.
  • the immunogenicity of the TNF Super Family variants is determined experimentally to confirm that the variants do have reduced or eliminated immunogenicity relative to the parent protein.
  • ex vivo T-cell activation assays are used to experimentally quantitate immunogenicity.
  • antigen presenting cells and na ⁇ ve T cells from matched donors are challenged with a peptide or whole protein of interest one or more times.
  • T cell activation can be detected using a number of methods, for example by monitoring production of cytokines or measuring uptake of tritiated thymidine.
  • interferon gamma production is monitored using Elispot assays (see Schstoff et. al. J.
  • T-cell assays include those disclosed in Meidenbauer, et al. Prostate 43, 88-100 (2000); Schultes, B.C and Whiteside, T.L., J. Immunol. Methods 279, 1-15 (2003); and Stickler, et al., J. Immunotherapy, 23, 654-660 (2000), all entirely incorporated by reference.
  • the PBMC donors used for the above-described T-cell activation assays will comprise class II MHC alleles that are common in patients requiring treatment for TNF Super Family responsive disorders. For example, for most diseases and disorders, it is desirable to test donors comprising all of the alleles that are prevalent in the population. However, for diseases or disorders that are linked with specific MHC alleles, it may be more appropriate to focus screening on alleles that confer susceptibility to TNF Super Family responsive disorders.
  • the MHC haplotype of PBMC donors or patients that raise an immune response to the wild type or variant TNF Super Family are compared with the MHC haplotype of patients who do not raise a response. This data may be used to guide preclinical and clinical studies as well as aiding in identification of patients who will be especially likely to respond favorably or unfavorably to the TNF Super Family therapeutic.
  • immunogenicity is measured in transgenic mouse systems.
  • mice expressing fully or partially human class II MHC molecules may be used.
  • immunogenicity is tested by administering the TNF Super Family variants to one or more animals, including rodents and primates, and monitoring for antibody formation.
  • Non- human primates with defined MHC haplotypes may be especially useful, as the sequences and hence peptide binding specificities of the MHC molecules in non-human primates may be very similar to the sequences and peptide binding specificities of humans.
  • genetically engineered mouse models expressing human MHC peptide-binding domains may be used (see for example Sonderstrup et. al. Immunol. Rev. 172: 335-343 (1999) and Forsthuber et. al. J. Immunol. 167: 119-125 (2001), entirely incorporated by reference).
  • the variant TNF Super Family proteins and nucleic acids of the invention find use in a number of applications.
  • the variant TNF Super Family proteins are administered to a patient to treat a TNF Super Family responsive disorder. Administration may be therapeutic or prophylactic.
  • the pharmaceutical compositions of the present invention comprise a variant TNF Super Family protein in a form suitable for administration to a patient.
  • the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
  • organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid,
  • “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
  • the pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers such as NaOAc; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.
  • carrier proteins such as serum albumin
  • buffers such as NaOAc
  • fillers such as microcrystalline cellulose, lactose, corn and other starches
  • binding agents such as microcrystalline cellulose, lactose, corn and other starches
  • sweeteners and other flavoring agents coloring agents
  • polyethylene glycol polyethylene glycol
  • the administration of the variant TNF Super Family proteins of the present invention may be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, parenterally, intrapulmonary, vaginally, rectally, or intraocularly.
  • the Variant TNF Super Family protein may be directly applied as a solution or spray.
  • the pharmaceutical composition may be formulated in a variety of ways.
  • a therapeutically effective dose of a variant TNF Super Family protein is administered to a patient in need of treatment.
  • the concentration of the therapeutically active variant TNF Super Family protein in the formulation may vary from about 0.1 to about 100 weight %. In another preferred embodiment, the concentration of the variant TNF Super Family protein is in the range of 0.003 to 1.0 molar, with dosages from 0.03, 0.05, 0.1 , 0.2, and 0.3 miUimoles per kilogram of body weight being preferred.
  • variant TNF Super Family nucleic acids may be administered; i.e., "gene therapy” approaches may be used.
  • variant TNF Super Family nucleic acids are introduced into cells in a patient in order to achieve in vivo synthesis of a therapeutically effective amount of variant TNF Super Family protein.
  • Variant TNF Super Family nucleic acids may be introduced using a number of techniques, including but not limited to transfection with liposomes, viral (typically retroviral) vectors, and viral coat protein-liposome mediated transfection [Dzau et al., Trends in Biotechnology 11 :205-210 (1993), entirely incorporated by reference].
  • the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc.
  • an agent that targets the target cells such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc.
  • proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo intemalization in cycling, proteins that target intracellular localization and enhance intracellular half- life.
  • the technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem.
  • Agretopes were predicted for the following alleles, each of which is present in at least 1% of the US population: DRB1*0101 , DRB1*0102, DRB1*0301 , DRB1*0401 , DRB1*0402, DRB1*0404, DRB1*0405, DRB1*0408, DRB1*0701 , DRB1*0801 , DRB1*1101 , DRB1*1102, DRB1*1104, DRB1*1301 , DRB1*1302, DRB1*1501, and DRB1*1502.
  • Table 2 Predicted MHC-binding agretopes in TNF SF members. Iscore, the number of alleles, and the percent of the population hit at 1%, 3%, and 5% thresholds are shown. Especially preferred agretopes are predicted to affect at least 10% of the population, using a 1 % threshold.
  • Table 3 Predicted MHC-binding agretopes in TNF SF members. DRB1 alleles that are predicted to bind to each allele at 1 %, 3%, 5% and 10% cutoffs are marked with “1", “3", "5" or "10" respectively.
  • Example 2 Identification of suitable less immunogenic sequences for MHC-binding agretopes in TNF SF members.
  • Alternate sequences were scored for immunogenicity and structural compatibility. Preferred alternate sequences were defined to be those sequences that are not predicted to bind to any of the 17 MHC alleles tested above using a 1% threshold, and that have a total BLOSUM62 score that is at least 80% of the wild type score.
  • B(wt) is the BLOSUM62 score of the wild type 9-mer
  • l(alt) is the percent of the US population containing one or more MHC alleles that are predicted to bind the alternate 9-mer at a 1 % threshold and is 0 for all variants listed in Table 4
  • B(alt) is the BLOSUM62 score of the alternate 9-mer.
  • Example 3 Identification of suitable less immunogenic sequences for MHC-binding agretopes as determined by PDA® technology.
  • Table 5 Each position in the agretopes of interest was analyzed to identify a subset of amino acid substitutions that are potentially compatible with maintaining the structure and function of the protein. PDA® technology calculations were run for each position of each nine-mer agretope and compatible amino acids for each position were saved. In these calculations, side-chains within 5 Angstroms of the position of interest were permitted to change conformation but not amino acid identity. The variant agretopes were then analyzed for immunogenicity.
  • TNF SF member variants designed for soluble expression, superagonism, dominant negative inhibition, and competitive inhibition.
  • Previously described TNF SF member variants have been designed for a number of improved properties, including but not limited to superagonism, dominant negative inhibition, competitive inhibition, and receptor specificity. All 9-mers for which Iscore is altered, relative to wild type, in one or more variants is shown below.
  • variants that do not have any new agretopes are developed for therapeutic use.
  • variants in which Iscore is reduced for one or more agretopes relative to wild type human TNF SF member are developed for therapeutic use.
  • SEQUENCE ID 1 (wild type human BAFF, extra-cellular domain underlined) MDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLSCCLTWSFYQ VAALQGDLASLRAELQGHHAEKLPAGAGAPKAGLEEAPAVTAGLKIFEPPAPGEGNSSQNSRNKRAV QGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDK TYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLD GDVTFFGALKLL
  • SEQUENCE ID 2 (wild type human RANKL, extra-cellular domain underlined) MRRASRDYTKYLRGSEEMGGGPGAPHEGPLHAPPPPAPHQPPAASRSMFVALLGLGLGQVVCSVA LFFYFRAQMDPNRISEDGTHCIYRILRLHENADFQDTTLESQDTKLIPDSCRRIKQAFQGAVQKELQHI VGSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSHKVSLSSWYHDRGWAKISNMTF SNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSE FHFYSINVGGFFKLRSGEEISIEVSNPSLLDPDQDATYFGAFKVRDID
  • SEQUENCE ID 3 (wild type human APRIL, extra-cellular domain underlined) MPASSPFLLAPKGPPGNMGGPVREPALSVALWLSWGAALGAVACAMALLTQQTELQSLRREVSRLQ GTGGPSQNGEGYPWQSLPEQSSDALEAWENGERSRKRRAVLTQKQKKQHSVLHLVPINATSKDDS DVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQWSREGQGRQETLFRC IRSMPSHPDRAYNSCYSAGVFHLHQGDILSVIIPRARAKLNLSPHGTFLGFVKL
  • SEQUENCE ID 4 (wild type human CD40L, extra-cellular domain underlined) MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLHEDFVFMKTIQ RCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEMQKGDQNPQIAAHVISEASSKTTSVL QWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILL RAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
  • SEQUENCE ID 5 (wild type human TRAIL, extra-cellular domain underlined) MAMMEVQGGPSLGQTCVLIVIFTVLLQSLCVAVTYVYFTNELKQMQDKYSKSGIACFLKEDDSYWDP NDEESMNSPCWQVKWQLRQLVRKMILRTSEETISTVQEKQQNISPLVRERGPQRVAAHITGTRGRS NTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTK NDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMD HEASFFGAFLVG

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne des protéines variantes existant à l'état naturel membres de la superfamille des facteurs de nécrose tumorale avec immunogénicité réduite. Cette invention concerne plus spécifiquement les protéines variantes BAFF, RANKL, TRAIL, CD40L et APRIL avec immunogénicité réduite.
PCT/US2005/018130 2004-05-21 2005-05-23 Membres de la superfamille des tnf avec immunogenicite modifiee WO2005113598A2 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US57330104P 2004-05-21 2004-05-21
US57339504P 2004-05-21 2004-05-21
US57320604P 2004-05-21 2004-05-21
US60/573,301 2004-05-21
US60/573,206 2004-05-21
US60/573,395 2004-05-21
US58831404P 2004-07-14 2004-07-14
US60/588,314 2004-07-14
US60739704P 2004-09-02 2004-09-02
US60739604P 2004-09-02 2004-09-02
US60/607,396 2004-09-02
US60/607,397 2004-09-02

Publications (2)

Publication Number Publication Date
WO2005113598A2 true WO2005113598A2 (fr) 2005-12-01
WO2005113598A3 WO2005113598A3 (fr) 2006-06-01

Family

ID=35428917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/018130 WO2005113598A2 (fr) 2004-05-21 2005-05-23 Membres de la superfamille des tnf avec immunogenicite modifiee

Country Status (1)

Country Link
WO (1) WO2005113598A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604178B2 (en) 2006-09-18 2013-12-10 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
US8956849B2 (en) 2007-11-01 2015-02-17 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to Eimeria
US8961990B2 (en) 2010-06-09 2015-02-24 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
EP3037544A1 (fr) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Procedes et compositions destinees au traitement de patients atteints de lupus erythematosus systémique positifs pour des auto-anticorps
US9603915B2 (en) 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US10682398B2 (en) 2016-05-03 2020-06-16 The Texas A&M University System Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
WO2022144384A1 (fr) * 2020-12-29 2022-07-07 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anticorps anti-april et leurs utilisations

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012965A2 (fr) * 1997-09-12 1999-03-18 Biogen, Inc. Nouveaux ligands de la famille des tnf
WO2000067034A1 (fr) * 1999-04-30 2000-11-09 Immunex Corporation Methodes d'utilisation de l'interaction taci/taci-l
WO2002018445A2 (fr) * 2000-09-01 2002-03-07 Biogen, Inc. Structure co-cristalline de l'anticorps monoclonal 5c8 et cd154, et utilisation de cette structure dans la mise au point de medicaments
WO2002036141A2 (fr) * 2000-11-02 2002-05-10 Immunex Corporation Methode permettant d'ameliorer des reponses immunitaires induites par des lymphocytes
US20020061525A1 (en) * 2000-05-16 2002-05-23 Rodrigo Yelin Sequences of trail variants
WO2003006154A2 (fr) * 2001-07-10 2003-01-23 Xencor, Inc. Automatisation de conception de proteines pour la conception de bibliotheques de proteines a antigenicite modifiee
WO2003029420A2 (fr) * 2001-10-02 2003-04-10 Genentech, Inc. Variants de ligands apo-2 et leurs utilisations
WO2003059281A2 (fr) * 2002-01-04 2003-07-24 Xencor Nouveaux variants de proteines rankl
WO2004081043A2 (fr) * 2003-01-06 2004-09-23 Xencor, Inc. Variants de baff et leurs methodes d'utilisation
WO2004089982A2 (fr) * 2003-01-06 2004-10-21 Xencor Variantes april et leurs procedes
WO2005035570A2 (fr) * 2003-10-10 2005-04-21 Xencor, Inc. Nouveaux variants de la proteine cd40l

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012965A2 (fr) * 1997-09-12 1999-03-18 Biogen, Inc. Nouveaux ligands de la famille des tnf
WO2000067034A1 (fr) * 1999-04-30 2000-11-09 Immunex Corporation Methodes d'utilisation de l'interaction taci/taci-l
US20020061525A1 (en) * 2000-05-16 2002-05-23 Rodrigo Yelin Sequences of trail variants
WO2002018445A2 (fr) * 2000-09-01 2002-03-07 Biogen, Inc. Structure co-cristalline de l'anticorps monoclonal 5c8 et cd154, et utilisation de cette structure dans la mise au point de medicaments
WO2002036141A2 (fr) * 2000-11-02 2002-05-10 Immunex Corporation Methode permettant d'ameliorer des reponses immunitaires induites par des lymphocytes
WO2003006154A2 (fr) * 2001-07-10 2003-01-23 Xencor, Inc. Automatisation de conception de proteines pour la conception de bibliotheques de proteines a antigenicite modifiee
WO2003029420A2 (fr) * 2001-10-02 2003-04-10 Genentech, Inc. Variants de ligands apo-2 et leurs utilisations
WO2003059281A2 (fr) * 2002-01-04 2003-07-24 Xencor Nouveaux variants de proteines rankl
WO2004081043A2 (fr) * 2003-01-06 2004-09-23 Xencor, Inc. Variants de baff et leurs methodes d'utilisation
WO2004089982A2 (fr) * 2003-01-06 2004-10-21 Xencor Variantes april et leurs procedes
WO2005035570A2 (fr) * 2003-10-10 2005-04-21 Xencor, Inc. Nouveaux variants de la proteine cd40l

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037544A1 (fr) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Procedes et compositions destinees au traitement de patients atteints de lupus erythematosus systémique positifs pour des auto-anticorps
US10004798B2 (en) 2006-09-18 2018-06-26 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
US8604178B2 (en) 2006-09-18 2013-12-10 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
US9226957B2 (en) 2006-09-18 2016-01-05 The Texas A&M University System Compositions and methods of enhancing immune responses
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
US8956849B2 (en) 2007-11-01 2015-02-17 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to Eimeria
US10842858B2 (en) 2007-11-01 2020-11-24 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to Eimeria
US10016493B2 (en) 2007-11-01 2018-07-10 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to Eimeria
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
US9913893B2 (en) 2010-01-21 2018-03-13 The Board Of Trustees Of The University Of Arkansas Vaccine vectors and methods of enhancing immune responses
US10960068B2 (en) 2010-06-09 2021-03-30 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
US8961990B2 (en) 2010-06-09 2015-02-24 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
US11364290B2 (en) 2013-02-14 2022-06-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10792351B2 (en) 2013-02-14 2020-10-06 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US9603915B2 (en) 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US10328137B2 (en) 2013-02-14 2019-06-25 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US9884099B2 (en) 2013-02-14 2018-02-06 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US11904005B2 (en) 2013-02-14 2024-02-20 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US10716840B2 (en) 2013-03-15 2020-07-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US11013792B2 (en) 2013-03-15 2021-05-25 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US10682398B2 (en) 2016-05-03 2020-06-16 The Texas A&M University System Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
US11382962B2 (en) 2016-05-03 2022-07-12 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
WO2022144384A1 (fr) * 2020-12-29 2022-07-07 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anticorps anti-april et leurs utilisations

Also Published As

Publication number Publication date
WO2005113598A3 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
Kayagaki et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2
Zhan et al. Decoy strategies: the structure of TL1A: DcR3 complex
Glenney et al. Early diversification of the TNF superfamily in teleosts: genomic characterization and expression analysis
Lang et al. Binding studies of TNF receptor superfamily (TNFRSF) receptors on intact cells
Felix et al. Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures
Wallweber et al. The crystal structure of a proliferation-inducing ligand, APRIL
Gong et al. CD154-CD40 interactions are essential for thymus-dependent antibody production in zebrafish: insights into the origin of costimulatory pathway in helper T cell-regulated adaptive immunity in early vertebrates
US7144987B1 (en) Protein based tumor necrosis factor-receptor variants for the treatment of TNF related disorders
US20030166559A1 (en) Dominant negative proteins and methods thereof
EP1673389A2 (fr) Nouveaux variants de la proteine cd40l
US20170088600A1 (en) Novel crystal structure and ligand binding sites of trail receptor
US20060014248A1 (en) TNF super family members with altered immunogenicity
WO2005113598A2 (fr) Membres de la superfamille des tnf avec immunogenicite modifiee
WO2004081043A2 (fr) Variants de baff et leurs methodes d'utilisation
US7994281B2 (en) Cytokine design
US20050181994A1 (en) Novel variants of CD40L protein
JP2008507591A (ja) 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
US9290582B2 (en) B cell activating factor antagonist and preparation method and use thereof
US20050130892A1 (en) BAFF variants and methods thereof
US7553930B2 (en) BAFF variants and methods thereof
WO2004089982A2 (fr) Variantes april et leurs procedes
US20050003480A1 (en) April variants and methods thereof
US20050221443A1 (en) Tumor necrosis factor super family agonists
Liu et al. Molecular cloning, expression, bioinformatics analysis, and bioactivity of TNFSF13 (APRIL) in the South African clawed frog (Xenopus laevi): a new model to study immunological diseases
Veny et al. TNF superfamily in inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载